Clear Street Group Inc. Invests $5.07 Million in Tharimmune, Inc. $THAR

Clear Street Group Inc. bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,671,836 shares of the company’s stock, valued at approximately $5,066,000.

Other large investors also recently made changes to their positions in the company. Franklin Resources Inc. bought a new position in Tharimmune in the second quarter valued at about $88,000. XTX Topco Ltd bought a new position in Tharimmune in the second quarter valued at about $25,000. Drucker Wealth 3.0 LLC bought a new position in Tharimmune in the third quarter valued at about $29,000. Essex LLC bought a new position in Tharimmune in the fourth quarter valued at about $31,000. Finally, Geode Capital Management LLC boosted its holdings in Tharimmune by 1,102.6% in the fourth quarter. Geode Capital Management LLC now owns 335,923 shares of the company’s stock valued at $1,018,000 after acquiring an additional 307,991 shares during the last quarter. Institutional investors own 1.16% of the company’s stock.

Tharimmune Stock Up 2.3%

Tharimmune stock opened at $3.09 on Friday. The business’s 50-day simple moving average is $3.18 and its 200 day simple moving average is $3.41. The stock has a market cap of $116.59 million, a price-to-earnings ratio of -0.77 and a beta of 1.43. Tharimmune, Inc. has a 12-month low of $0.95 and a 12-month high of $9.08.

Tharimmune Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.